Über uns

À propos de nous

Open Access

Karriere

Carrière

Aboverträge Kündigen

Résiliation d’abonnement

Vertrag widerrufen

Résiliation de contrat 

Datenschutz

Protection des données

Impressum

Mentions légales

Barrierefreiheit

Accessibilité

Zahlung und Lieferung

Paiement et livraison

Libra

Was ist Libra?

C'est quoi Libra ?

Kostenlos testen

Tester gratuitement

LEXIA

LEXIA Arbeitsrecht

Was ist LEXIA?

C'est quoi LEXIA ?

LEXIA Familienrecht

Zeitschriften

Revues

recht

Pflegerecht

ZBJV

forumpoenale

ZStrR

Anwaltsrevue

Revue de l'avocat

RSAS

FamPra.ch

ASYL

Life Science Recht

BlAR

Sachbuch

Livres spécialisés

LOKI

Semaphor

Fokusthemen

Focus

Thema

Recht studieren

Arbeitsrecht

Droit du travail

Studium

Études

Familienrecht

Droit de la famille

Sozialversicherungsrecht

Droit des assurances sociales

Strafrecht

Droit pénal

Aktienrecht

Droit des sociétés anonymes

Persönlichkeitsrecht

Droit de la personnalité

Publikationen

Publications

Literatur

Digitales Angebot

Bücher

Livres

Buchreihen

Collections

Onlinemodule LEXIA

Modules en ligne LEXIA

recht.ch

Studienliteratur

Littérature pour les études

Swisslex

Dienstleistungen

Services

Dienstleistungen für

Corporate Books

Publishing Lösungen

Aktuelles

Geschäftskunden

Professionnels

Corporate Publishing

Content solutions

Buchhandlungen

Librairies

Veranstaltungen

Événements

Presse

Dozierende

Enseignants

Studierende

Étudiants

Inserierende

Annonceurs

Newsletter

Blog

Autorinnen/Autoren

Auteurs

Unsere Schreibenden

Hilfe

Unsere Autorinnen und Autoren

Liste

Autorenlounge

Espace des auteurs

Bei uns publizieren

Publier chez nous

Open Access Policy

Verlag

Éditions

Themen

Mehr wissen

Mitarbeitende

Collaborateurs

Geschichte

Histoire

Unser Magazin

Notre magazine

Vision und Mission

Vision et mission

Partner

Partenaires

Unternehmenskultur

Culture d'entreprise

Kontakt

Contact

Shop

Schweizer Recht

Ausländisches Recht

Über unseren Shop

Neuerscheinungen

Nouveautés

Sortiment & Suche

Catalogue & Recherche

Vorankündigungen

À paraître

Nach Rechtsgebiet

Par domaine juridique

Kommentare

Commentaires

Gesamtkatalog

Catalogue complet

Fachkatalog Recht

Catalogue de droit

Mccaffrey P: An Introduction to
Healthcare Informatics

An Introduction to Healthcare Informatics

Building Data-Driven Tools

“As gripping and important as Patrick Radden Keefe’s Empire of Pain and Gardiner Harris’ No More Tears, The Pain Brokers is a righteous bolt of reportage worthy of acclaim.” —Booklist, starred review Selling the Dream meets Empire of Pain in this shocking, never-told-before story of three women caught in a web of telemarketing scammers, shady doctors, and profit-hungry lawyers who turned fears surrounding a faulty medical device affecting millions of women into a goldmine. For decades, late-night television has blared a familiar refrain: If you or a loved one has been injured by X product… But behind those ads lies a lesser-known world where elaborate scams revictimize the injured. Why else would thousands of women with health insurance take out loans with astronomical interest rates and fly to south Florida to have their pelvic mesh surgically removed at a chiropractor’s clinic? The Pain Brokers, by law professor Elizabeth Burch, is a “pulse-pounding legal thriller” (Eric Eyre, Pulitzer Prize winner) and damning investigation of a scheme made possible by a medical and legal complex that too often views women’s bodies as cash machines and fails to take their pain seriously. As Burch unfurls each level to the scheme, we meet an enthralling cast of characters, from a world class scam artist who reaped tens of millions of dollars at a south Florida call center, to the ultimate white shoe power lawyer who defended Big Pharma but became an unlikely hero, to a newly minted small-town Arkansas attorney who advocated for the unseen and unheard. But at the center are three women, Jerri, Barb, and Sharon, whose lives were upended by the very procedure they were told would save them. A page-turning, urgently necessary work of public service journalism, The Pain Brokers is not only a chilling exposé of a legal system gone awry, but a wake-up call to the ways in which it harms those it is meant to help.

How Con Men, Call Centers, and Rogue Doctors Fuel America's Lawsuit Factory

The Pain Brokers

'A terrifying story of profit before patients, and a chilling glimpse of what can happen when private companies are allowed to take charge of healthcare.' Gavin Francis Six decades ago, researchers achieved the impossible: developing a treatment that transformed kidney failure from a death sentence to a manageable condition. Yet, in the hands of a predatory medical industry, this triumph led to skyrocketing costs and worsening care. A gripping account of privatised healthcare gone wrong, How to Make a Killing recounts how the optimism of the 1950s and 1960s - when transplants and dialysis machines offered hope - gave way to anguished debates about the ethics of rationing and profiting from life-saving care, and how Big Dialysis proliferated at the expense of its patients. A triumph of investigative research, Tom Mueller's book features an unforgettable cast of characters: CEOs who dress as musketeers to exhort more aggressive profit-seeking, nephrologist insiders who reveal the substandard care this causes, and heroic patients who risk their lives to reveal the truth.

How life-saving medicine became a for-profit enterprise that threatens the people it is meant to save

Death, Dollars and the Business of Blood

How to Make a Killing

Independently published

What happens behind the medicines we see on pharmacy shelves?The pharmaceutical industry is far bigger than pills, injections, and prescriptions. Behind every successful medicine is a vast ecosystem of research, diagnostics, clinical trials, manufacturing, testing, packaging, logistics, technology, and specialized services.Beyond the Pill takes you inside these lesser-known businesses and reveals how major pharmaceutical companies create value beyond the medicine itself.Inside this book, you'll discover: <ul><li>Hidden businesses operating around major pharmaceutical companies</li><li>Human plasma collection and processing</li><li>Diagnostics and personalized medicine</li><li>Clinical research and CROs</li><li>Contract manufacturing and CDMOs</li><li>Biotech and antibody discovery</li><li>Vaccine and cold-chain ecosystems</li><li>Drug delivery and pharmaceutical packaging</li><li>mRNA and biological manufacturing</li><li>Medical devices and specialty healthcare services</li><li>Practical entry points for smaller businesses and entrepreneurs</li><li>Indicative investment ranges and revenue models</li><li>Common problems, risks, and barriers to entry</li><li>Beginner strategies for entering the wider pharma ecosystem</li></ul>This book is not about becoming the next pharmaceutical giant. It is about learning to see the businesses surrounding the giants.For entrepreneurs, investors, professionals, and curious readers, Beyond the Pill offers a practical look at the hidden infrastructure that makes modern healthcare possible.Look beyond the medicine. Discover the business behind it.

The Business You Never See: Hidden Opportunities Behind Drugs, Diagnostics & Healthcare

Pharma

Artificial Intelligence in Precision Drug Design: Advanced Applications showcases how artificial intelligence (AI) is revolutionizing modern drug discovery and development. Building upon the foundational principles established in Volume 1, this book dives into real-world applications where AI accelerates innovation, enhances predictive accuracy, and enables breakthrough therapeutics. Featuring contributions from leading global researchers and practitioners, the book explores machine learning, deep learning, and network-based approaches applied to complex biomedical challenges. Key areas include AI driven drug repurposing, combination therapies, immunotherapy, vaccine design, quantum computing, and the integration of large language models in drug discovery. Additional chapters highlight predictive modeling using electronic health records, AI-powered medical imaging, and explainable AI for structure-based drug design. What sets this volume apart is its emphasis on practical impact, demonstrating how data, computation, and interdisciplinary collaboration converge to advance precision medicine. Designed for scientists, clinicians, educators, and students, it serves as both a comprehensive reference and a source of inspiration for leveraging AI to transform healthcare.

Foundations and Core Techniques

Artificial Intelligence in Precision Drug Design, Volume 1

The Indian Pharmaceutical Industry (IPI) has grown exponentially over the last few decades; however, recent global competition is forcing the industry to examine its performance focusing on productivity, efficiency and growth capabilities. While the industry as a whole has proved resilient to economic slowdowns, the performance of individual firms in the industry have displayed large disparities. There is also evidence of disparity among the Indian states. Efficiency and productivity act as good performance indicators. Performance Analysis of the Indian Pharmaceutical Industry estimates the extent of technical efficiency (TE) and total factor productivity growth (TFPG) of IPI and to identify their major affecting factors. A comparison between efficiency and TFPG of IPI is made, looking at the common factors responsible for variations in efficiency and TFPG of IPI. Chakraborty and Pal examine the import and export of Indian medicines to understand the place of the industry on a global scale and assess what can be done to become more competitive. The international comparison of this study will appeal and be useful for researchers, industry professionals and policy makers.

A Global Outlook

Performance Analysis of the Indian Pharmaceutical Industry

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer's

Doctored

Artificial Intelligence and Machine Learning in Healthcare discusses the potential of groundbreaking technologies on the delivery of care. A lot have been said about how artificial intelligence and machine learning can improve healthcare, however there are still many doubts and concerns among health professionals, all of which are addressed in this book. Sections cover History and Basic Overview of AI and ML, with differentiation of supervised, unsupervised and deep learning, Applications of AI and ML in Healthcare, The Future of Healthcare with AI, Challenges to Adopting AI in Healthcare, and ethics and legal processes for implementation. This book is a valuable resource for bioinformaticians, clinicians, graduate students and several members of biomedical field who needs to get up to speed on the revolutionary role of AI and Machine Learning in healthcare.

Artificial Intelligence and Machine Learning in Healthcare

"An essential read for anyone committed to understanding the technologies that will define our future." CHRISTIAN ANGERMAYER, BIOTECH ENTREPRENEUR AND FOUNDER OF APEIRON INVESTMENT GROUP Welcome to the biotech revolution In the last century, technology has transformed the human experience across the world. This has been super-charged by the arrival of the internet, smart phones, AI and machine learning, and created trillion-plus dollar companies and household names like Apple, Amazon, Google and Microsoft. Our Future is Biotech explains why biotech is next: because our biggest remaining challenges as a species concern biological systems. Biotech companies will solve our most intractable problems, from cancer, dementia, obesity and diabetes to elderly care, mental health conditions, and even clean power generation, agricultural production and environmental degradation. Biotech means that we can all live better, safer, healthier, wealthier, happier, and longer lives. The industry has already delivered "miracle cures" for several diseases, and there is more to come. But despite this, few people are aware of the phenomenal progress being made. Our Future is Biotech addresses this, explaining what biotech is, what is coming next, and how you might profit from it too. Tech has been the most important theme for human progress for the last century. Biotech is next.

"An essential read for anyone committed to understanding the technologies that will define our future." CHRISTIAN ANGERMAYER, BIOTECH ENTREPRENEUR AND FOUNDER OF APEIRON INVESTMENT GROUP Welcome to the biotech revolution In the last century, technology has transformed the human experience across the world. This has been super-charged by the arrival of the internet, smart phones, AI and machine learning, and created trillion-plus dollar companies and household names like Apple, Amazon, Google and Microsoft. Our Future is Biotech explains why biotech is next: because our biggest remaining challenges as a species concern biological systems. Biotech companies will solve our most intractable problems, from cancer, dementia, obesity and diabetes to elderly care, mental health conditions, and even clean power generation, agricultural production and environmental degradation. Biotech means that we can all live better, safer, healthier, wealthier, happier, and longer lives. The industry has already delivered "miracle cures" for several diseases, and there is more to come. But despite this, few people are aware of the phenomenal progress being made. Our Future is Biotech addresses this, explaining what biotech is, what is coming next, and how you might profit from it too. Tech has been the most important theme for human progress for the last century. Biotech is next.

A Plain English Guide to How a Tech Revolution is Changing Our Lives and Our Health for the Better

Our Future is Biotech

"A practical guide based on the real-life experiences of Indian industries."

5S to Operational Excellence

In 2002, John Maraganore left the leadership of an established biotech company with an ambition many thought implausible. Small RNA molecules had been found to stop cells making specific proteins by destroying messenger RNAs. It was one of biology's most exciting recent discoveries. But it seemed unlikely that this RNA interference (RNAi) could ever be applied therapeutically. The molecules were hard to work with and there was no technology for delivering them where they would be needed. Skeptics were plentiful and success unlikely. Nevertheless, Maraganore joined a group of visionary scientists in Cambridge MA to become the founding CEO of Alnylam Pharmaceuticals, intent on creating RNAi-based medicines. The Importance of Being Unreasonable is Maraganore's inside account of the two-decade pursuit of an unproven idea and its culmination in creating an entirely new class of medicines capable of silencing disease-causing genes. Along the way, Alnylam faced seemingly intractable scientific problems in chemistry and drug delivery as well as huge challenges in clinical development, financing, and commercialization. Maraganore describes exhilarating breakthroughs and devastating failures, fierce competitors and indispensable collaborators, and bold strategic bets and times of peril for the company's survival. Yet the conviction that transformative science demanded rigorous evidence as well as the willingness to flout conventional wisdom resulted in the development and global deployment of five RNAi-based therapeutics before Maraganore stepped down in 2021. Part scientific adventure, part company-building story, and part reflection on scientific leadership, this book offers a rare view of the biotechnology industry from the inside. Maraganore shows how company culture, resilience, calculated risk, and an unwavering focus on patients can turn scientific possibilities into medicines, and how progress often depends on people unreasonable enough to persist when others say it cannot be done.

The Importance of Being Unreasonable: Building a Company on the Frontiers of Science and Medicine

The book celebrating 100 years since the founding of the historic Italian multinational company. In the early 1920s, Oronzio De Nora was a young electrochemistry researcher at Politecnico di Milano. Experimenting with a new electrolytic cell, he cut his finger; he dipped the wound into the plant¿s oxygenated and electrified solution and invented Amuchina, a chlorine disinfectant. A touch of luck, a touch of genius. Over the course of the 20th century, the De Nora company became a world leader in the production of chlorine and soda; it developed hundreds of patents and established itself as one of the key drivers for industrial development. After a century of history and three De Nora generations, the company is now a multinational group, listed on the Stock Exchange, looking towards the sustainable future of the planet, energy conversion, and decarbonization. There is always an electrolytic cell behind the most advanced forms of green hydrogen production and water purification treatments. De Nora. Stories from a century of life recounts this exciting race towards the future. Luca Masia has written it in the form of short stories, in a narrative style that captivates the reader¿s attention from the very first pages. With an artist¿s gaze, Luca Campigotto ¿ one of the most widely appreciated Italian photographers on the international scene ¿ has documented the complex reality of De Nora: research laboratories, large-scale production, and specialized technicians. Its words and images illustrate a journey of scientific discoveries and technological innovations undertaken with ingenuity and dedication, while always putting people at the heart of the enterprise.

Stories from a century of life

De Nora

The global healthcare landscape is profoundly transformed, driven by technological advancements, demographic shifts, evolving patient expectations, and new economic paradigms.The New Health Economy explores how emerging innovations-such as artificial intelligence (AI), personalized medicine, digital health solutions, and value-based care-reshape healthcare delivery, costs, and accessibility. This book will provide a roadmap for leaders to navigate the future of healthcare while addressing challenges related to ethics, equity, regulation, and sustainability. Drawing upon cutting-edge research, expert insights, and real-world case studies, The New Health Economy presents a compelling vision of healthcare's future and the economic forces driving it. The book blends economic theory with practical solutions, demonstrating how key players-from government agencies and hospitals to startups and Big Tech-are redefining healthcare systems globally. The healthcare industry is at an inflexion point. Traditional models are struggling with rising costs, ageing populations, and the burden of chronic diseases. Meanwhile, innovations in digital health, data analytics, and biotechnology offer unprecedented opportunities to enhance patient outcomes and economic efficiency.This is a timely, research-backed book that provides a comprehensive, forward-thinking guide for navigating the rapid transformations in healthcare. By blending economic analysis with healthcare innovation, it offers readers an invaluable resource for understanding not just where healthcare is going, but how to shape its future.

Navigating Innovation, Equity, and the Future of Care

The New Health Economy

An Introduction to Healthcare Informatics

Weitere Titel zum Thema